Consensus nomenclature for CD8(+) T cell phenotypes in cancer

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jaeger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, Van Der Burg SH, Van Der Bruggen P, Van Den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Book Volume: 4

Pages Range: e998538

Journal Issue: 4

DOI: 10.1080/2162402X.2014.998538

Abstract

Whereas preclinical investigations and clinical studies have established that CD8(+) T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8(+) T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8(+) T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8(+) T cell immunity, leading to the emergence of dysfunctional CD8(+) T cells. The existence of different types of CD8(+) T cells in cancer calls for a more precise definition of the CD8(+) T cell immune phenotypes in cancer and the abandonment of the generic terms "pro-tumor" and "antitumor." Based on recent studies investigating the functions of CD8(+) T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8(+) T cells in cancer.

Authors with CRIS profile

Involved external institutions

Rutgers Cancer Institute of New Jersey United States (USA) (US) University of Pittsburgh United States (USA) (US) Universitätsklinikum Heidelberg Germany (DE) Icahn School of Medicine at Mount Sinai United States (USA) (US) University of Miami United States (USA) (US) Wistar Institute United States (USA) (US) University of Paris 5 - René Descartes / Université Paris V René Descartes France (FR) University of Queensland Australia (AU) Dana–Farber Cancer Institute United States (USA) (US) Université de Lausanne (UNIL) Switzerland (CH) University of California Los Angeles (UCLA) United States (USA) (US) Fondazione IRCCS: Istituto Nazionale dei Tumori Italy (IT) Yale University United States (USA) (US) Augusta University United States (USA) (US) University of Turin / Università degli Studi di Torino (UNITO) Italy (IT) National Institute for Health and Medical Research / Institut national de la santé et de la recherche médicale (INSERM) France (FR) National Center for Scientific Research / Centre national de la recherche scientifique (CNRS) France (FR) Centre Léon-Bérard (UNICANCER) France (FR) Harvard University United States (USA) (US) National Cancer Institute (NCI) United States (USA) (US) Johns Hopkins University (JHU) United States (USA) (US) University of Michigan United States (USA) (US) Sidra Medical and Research Center Qatar (QA) Université Catholique de Louvain (UCL) Belgium (BE) Leiden University Netherlands (NL) University of Connecticut United States (USA) (US) Washington University United States (USA) (US) University Hospital Siena Italy (IT) Jackson Laboratory for Genomic Medicine United States (USA) (US) University of Texas MD Anderson Cancer Center United States (USA) (US) Roswell Park Cancer Institute United States (USA) (US) Universidad de Navarra Spain (ES) Istituto Clinico Humanitas Italy (IT) Al Amal Hospital Qatar (QA) Karolinska Institute Sweden (SE) Ben-Gurion University of the Negev (BGU) / אוניברסיטת בן-גוריון בנגב Israel (IL) Laboratoires Servier France (FR) QIMR Berghofer Medical Research Institute (früher: the Queensland Institute of Medical Research) Australia (AU)

How to cite

APA:

Apetoh, L., Smyth, M.J., Drake, C.G., Abastado, J.-P., Apte, R.N., Ayyoub, M.,... Anderson, A.C. (2015). Consensus nomenclature for CD8(+) T cell phenotypes in cancer. OncoImmunology, 4(4), e998538. https://doi.org/10.1080/2162402X.2014.998538

MLA:

Apetoh, Lionel, et al. "Consensus nomenclature for CD8(+) T cell phenotypes in cancer." OncoImmunology 4.4 (2015): e998538.

BibTeX: Download